Literature DB >> 8886861

Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720.

S Enosawa1, S Suzuki, T Kakefuda, X K Li, H Amemiya.   

Abstract

A novel immunosuppressant, FTY720, induces a rapid and marked decrease of peripheral lymphocytes, and prolong allograft survival in rats. Its mechanism of action is mediated by apoptotic cell death. In this study, we determined the time-related changes in the numbers of total lymphocytes, and the ratios of lymphocyte subpopulations in peripheral blood and lymphomyeloid organs in rats after the single oral administration of FTY720 (10 mg/kg), comparing with the effects of cyclophosphamide (80 mg/kg, ip). Total number of peripheral lymphocytes decreased significantly 3 h after the administration of the drug, while that of polymorphonuclear cells increased. T-cells were markedly decreased in number and reached a minimum of 2.3% of the control 3 days after the treatment, while B-cells reached 19.7%. T-cells decreased in spleen and liver but there was no notable change in thymus, lymph nodes, and bone marrow. The susceptibility of the cells against the drug was variant based on the type and the source of cells in vitro. Polymorphonuclear cells were the most resistant and lymph node cells the most sensitive to FTY720 after 3 h incubation with different concentration of the drug (1, 10,100 mumol/l). When incubated with 10 mumol/l of FTY720, B-cells were significantly higher in viability than the whole T- or CD4-cells. These results demonstrated that FTY720 induces cell death selectively in mature T-lymphocytes, especially CD4-lymphocytes, in peripheral blood without the depression of bone marrow.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886861     DOI: 10.1016/0162-3109(96)00132-4

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  15 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 2.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

Review 3.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

4.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

5.  A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes.

Authors:  S Suzuki; X K Li; S Enosawa; T Shinomiya
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

6.  The role of sphingosine 1-phosphate in immunity and sepsis.

Authors:  Markus H Gräler
Journal:  Am J Clin Exp Immunol       Date:  2012-09-27

7.  T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2.

Authors:  Yukitoshi Nagahara; Masahiko Ikekita; Takahisa Shinomiya
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

8.  Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis.

Authors:  Fang Wang; Wenfeng Tan; Dunming Guo; Xiaomin Zhu; Keqing Qian; Shaoheng He
Journal:  Int J Mol Sci       Date:  2010-09-02       Impact factor: 5.923

9.  FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells.

Authors:  Jingyu Jiang; Xiaodong Huang; Yi Wang; Aiping Deng; Jianhua Zhou
Journal:  Mol Biol Rep       Date:  2012-05-12       Impact factor: 2.316

Review 10.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.